Rob Quinn, a chartered accountant and biochemistry expert, has been appointed chief financial officer of Pharnext SA of France which is developing therapies for neurodegenerative diseases. He will take over from Valérie Worrall.
Dr Quinn joins Pharnext from BenevolentAI Ltd, an artificial intelligence specialist, where he was CFO. Prior to this he served as CFO at Silence Therapeutics Plc where he led the company’s listing on Nasdaq in 2020. Dr Quinn holds a PhD in biochemistry from the University of Manchester, UK.
Pharnext announced the appointment on 1 September 2022.
Copyright 2022 Evernow Publishing Ltd